FDA has approved rusfertide, a groundbreaking therapy that promises to spare patients with polycythemia vera (PV) repeated phlebotomies, the agency and officials from Takeda and P ...

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk. Despite advances in recent years, treatment choices ...

T-cell therapy has transformed outcomes in several blood cancers, but its success is far from uniform. According to Kerry ...

MINT randomized 238 patients to inebilizumab 300 mg IV vs placebo with a protocol-driven taper to prednisone ≤5 mg/day and ...

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy ...

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally ...

A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that ...